Product Description
OL-101 is a potentially best-in-class dual-targeting CAR-T for multiple myeloma that is on track for human clinical testing in the fourth quarter of 2024. Overland aims to target post-BCMA relapsed refractory multiple myeloma patients with the potential to move into earlier lines of therapy. (Sourced from: https://www.overlandpharma.com/overland-pharmaceuticals-announces-presentations-at-asgct-annual-meeting-for-novel-cell-therapies-for-oncology-and-autoimmune-diseases/)
Mechanisms of Action: CAR-T,BCMA,GPRC5D
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|